A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Phase 2 Active not recruiting 208 enrolled Janssen Research & Development, LLC

NaSingle-groupOpen-labelTreatment

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Evaluation	Drug	Modality	Dose	Route
Subject	Cilta-cel	Cell therapy	—	Intravenous
Background	Bortezomib	Small molecule	—	Subcutaneous
Background	Daratumumab	Monoclonal antibody	—	Subcutaneous
Background	Dexamethasone	Small molecule	—	Oral
Background	Lenalidomide	Other / unclassified	—	Oral